Thalidomide upper limb embryopathy - pathogenesis, past and present management and future considerations
- PMID: 37226469
- PMCID: PMC10466950
- DOI: 10.1177/17531934231177425
Thalidomide upper limb embryopathy - pathogenesis, past and present management and future considerations
Abstract
This review article provides a comprehensive overview of thalidomide upper limb embryopathy including updates about its pathogenesis, a historical account of the management of the paediatric thalidomide patient, experience with management of the adult patient, as well as creating awareness about early onset age-related changes associated with limb differences. Despite its withdrawal from the market in November 1961, novel discoveries have meant thalidomide is licensed again and currently still in use to treat a variety of conditions, including inflammatory disorders and some cancers. Yet, if not used safely, thalidomide still has the potential to cause damage to the embryo. Recent work identifying thalidomide analogues that retain clinical benefits yet without the harmful effects are showing great promise. Understanding the problems thalidomide survivors face as they age can allow surgeons to support their unique healthcare issues and translate these principles of care to other congenital upper limb differences.
Keywords: Thalidomide; cereblon; embryopathy; radial dysplasia; reversed shoulder.
Conflict of interest statement
The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures





Similar articles
-
Age-related changes in patients with upper limb thalidomide embryopathy in the United Kingdom.J Hand Surg Eur Vol. 2023 Sep;48(8):773-780. doi: 10.1177/17531934231164093. Epub 2023 Apr 6. J Hand Surg Eur Vol. 2023. PMID: 37021538 Free PMC article.
-
Commentary on Markiewicz et al. Age-related changes in patients with upper limb thalidomide embryopathy in the United Kingdom.J Hand Surg Eur Vol. 2023 Sep;48(8):781-782. doi: 10.1177/17531934231175304. Epub 2023 May 21. J Hand Surg Eur Vol. 2023. PMID: 37211796 No abstract available.
-
Integrative Role of the SALL4 Gene: From Thalidomide Embryopathy to Genetic Defects of the Upper Limb, Internal Organs, Cerebral Midline, and Pituitary.Horm Res Paediatr. 2024;97(2):106-112. doi: 10.1159/000531452. Epub 2023 Jun 7. Horm Res Paediatr. 2024. PMID: 37285827 Free PMC article. Review.
-
CRL4-Cereblon complex in Thalidomide Embryopathy: a translational investigation.Sci Rep. 2020 Jan 21;10(1):851. doi: 10.1038/s41598-020-57512-x. Sci Rep. 2020. PMID: 31964914 Free PMC article.
-
[Thalidomide embryopathy 60 years].Dtsch Med Wochenschr. 2022 Dec;147(24-25):1635-1638. doi: 10.1055/a-1951-0792. Epub 2022 Dec 5. Dtsch Med Wochenschr. 2022. PMID: 36470274 Review. German.
Cited by
-
Embryonic development grand challenge: crosslinking advances.Front Cell Dev Biol. 2024 Sep 19;12:1467261. doi: 10.3389/fcell.2024.1467261. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39364136 Free PMC article.
-
Targeting neuroinflammation: 3-monothiopomalidomide a new drug candidate to mitigate traumatic brain injury and neurodegeneration.J Biomed Sci. 2025 Jun 16;32(1):57. doi: 10.1186/s12929-025-01150-w. J Biomed Sci. 2025. PMID: 40524167 Free PMC article.
References
-
- Asatsuma-Okumura T, Ando H, Simone MD, et al.. P63 is a cereblon substrate involved in thalidomide teratogenicity. Nat Chem Biol. 2019, 15: 1077–84. - PubMed
-
- Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol. 1998, 55: 1827–34. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous